WGO Graded Evidence: Management of Acute Viral Hepatitis

Level: Clinical Trials: 6 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	A randomized controlled trial of lamivudine to treat acute hepatitis B. M Kumar, S Satapathy, R Monga, K Das, S Hissar, C Pande, BC Sharma, SK Sarin, Hepatology. 2007 Jan:97-101
	Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. SM Kamal, AE Fouly, RR Kamel, B Hockenjos, A Al Tawil, KE Khalifa, Q He, MJ Koziel, KM El Naggar, J Rasenack, NH Afdhal, Gastroenterology. 2006 Mar:632-8
	Duration of peginterferon therapy in acute hepatitis C: a randomized trial. SM Kamal, KN Moustafa, J Chen, J Fehr, A Abdel Moneim, KE Khalifa, LA El Gohary, AH Ramy, MA Madwar, J Rasenack, NH Afdhal, Hepatology. 2006 May:923-31
Supplementary evidence:
	Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. H Nomura, S Sou, H Tanimoto, T Nagahama, Y Kimura, J Hayashi, H Ishibashi, S Kashiwagi, Hepatology. 2004 May:1213-9
	Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C. P Fabris, G Tositti, MT Giordani, D Infantolino, LF de, Am J Gastroenterol. 2002 Feb:492-3
	Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. J Delwaide, N Bourgeois, C Gérard, S De Maeght, F Mokaddem, E Wain, B Bastens, J Fevery, M Géhénot, O Le Moine, JP Martinet, G Robaeys, B Servais, M Van Gossum, H Van Vlierberghe, Belgian Association for the Study of the Liver (BASL), Aliment Pharmacol Ther. 2004 Jul 1:15-22